Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) Clinical Trials in Seattle, Washington

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)